Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Assessing the duration of immunity following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a first priority to gauge the degree of protection following infection. Such knowledge is lacking, especially in the general population. Here, we studied changes in immunoglobulin isotype seropositivity and immunoglobulin G (IgG) binding strength of SARS-CoV-2-specific serum antibodies up to 7 months following onset of symptoms in a nationwide sample.
METHODS: Participants from a prospective representative serological study in the Netherlands were included based on IgG seroconversion to the spike S1 protein of SARS-CoV-2 (N = 353), with up to 3 consecutive serum samples per seroconverted participant (N = 738). Immunoglobulin M (IgM), immunoglobulin A (IgA), and IgG antibody concentrations to S1, and increase in IgG avidity in relation to time since onset of disease symptoms, were determined.
RESULTS: While SARS-CoV-2-specific IgM and IgA antibodies declined rapidly after the first month after disease onset, specific IgG was still present in 92% (95% confidence interval [CI], 89%-95%) of the participants after 7 months. The estimated 2-fold decrease of IgG antibodies was 158 days (95% CI, 136-189 days). Concentrations were sustained better in persons reporting significant symptoms compared to asymptomatic persons or those with mild upper respiratory complaints only. Similarly, avidity of IgG antibodies for symptomatic persons showed a steeper increase over time compared with persons with mild or no symptoms (P = .022).
CONCLUSIONS: SARS-CoV-2-specific IgG antibodies persist and show increasing avidity over time, indicative of underlying immune maturation. These data support development of immune memory against SARS-CoV-2, providing insight into protection of the general unvaccinated part of the population.
CLINICAL TRIALS REGISTRATION: NL8473 (the Dutch trial registry).
| Errataetall: |
CommentOn: Clin Infect Dis. 2021 Dec 16;73(12):2163-2165. - PMID 33730754 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 12 vom: 16. Dez., Seite 2155-2162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
den Hartog, Gerco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Avidity/maturation |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 08.11.2023 published: Print CommentOn: Clin Infect Dis. 2021 Dec 16;73(12):2163-2165. - PMID 33730754 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciab172 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321830733 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321830733 | ||
| 003 | DE-627 | ||
| 005 | 20231225180728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciab172 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321830733 | ||
| 035 | |a (NLM)33624751 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a den Hartog, Gerco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Clin Infect Dis. 2021 Dec 16;73(12):2163-2165. - PMID 33730754 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Assessing the duration of immunity following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a first priority to gauge the degree of protection following infection. Such knowledge is lacking, especially in the general population. Here, we studied changes in immunoglobulin isotype seropositivity and immunoglobulin G (IgG) binding strength of SARS-CoV-2-specific serum antibodies up to 7 months following onset of symptoms in a nationwide sample | ||
| 520 | |a METHODS: Participants from a prospective representative serological study in the Netherlands were included based on IgG seroconversion to the spike S1 protein of SARS-CoV-2 (N = 353), with up to 3 consecutive serum samples per seroconverted participant (N = 738). Immunoglobulin M (IgM), immunoglobulin A (IgA), and IgG antibody concentrations to S1, and increase in IgG avidity in relation to time since onset of disease symptoms, were determined | ||
| 520 | |a RESULTS: While SARS-CoV-2-specific IgM and IgA antibodies declined rapidly after the first month after disease onset, specific IgG was still present in 92% (95% confidence interval [CI], 89%-95%) of the participants after 7 months. The estimated 2-fold decrease of IgG antibodies was 158 days (95% CI, 136-189 days). Concentrations were sustained better in persons reporting significant symptoms compared to asymptomatic persons or those with mild upper respiratory complaints only. Similarly, avidity of IgG antibodies for symptomatic persons showed a steeper increase over time compared with persons with mild or no symptoms (P = .022) | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2-specific IgG antibodies persist and show increasing avidity over time, indicative of underlying immune maturation. These data support development of immune memory against SARS-CoV-2, providing insight into protection of the general unvaccinated part of the population | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NL8473 (the Dutch trial registry) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a avidity/maturation | |
| 650 | 4 | |a decay | |
| 650 | 4 | |a immunoglobulin G | |
| 650 | 4 | |a symptoms | |
| 700 | 1 | |a Vos, Eric R A |e verfasserin |4 aut | |
| 700 | 1 | |a van den Hoogen, Lotus L |e verfasserin |4 aut | |
| 700 | 1 | |a van Boven, Michiel |e verfasserin |4 aut | |
| 700 | 1 | |a Schepp, Rutger M |e verfasserin |4 aut | |
| 700 | 1 | |a Smits, Gaby |e verfasserin |4 aut | |
| 700 | 1 | |a van Vliet, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Woudstra, Linde |e verfasserin |4 aut | |
| 700 | 1 | |a Wijmenga-Monsuur, Alienke J |e verfasserin |4 aut | |
| 700 | 1 | |a van Hagen, Cheyenne C E |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Elisabeth A M |e verfasserin |4 aut | |
| 700 | 1 | |a de Melker, Hester E |e verfasserin |4 aut | |
| 700 | 1 | |a van der Klis, Fiona R M |e verfasserin |4 aut | |
| 700 | 1 | |a van Binnendijk, Robert S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 12 vom: 16. Dez., Seite 2155-2162 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:12 |g day:16 |g month:12 |g pages:2155-2162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab172 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 12 |b 16 |c 12 |h 2155-2162 | ||